Guided Therapeutics (GTHP) Notes Payables (2011 - 2025)
Guided Therapeutics (GTHP) reported Notes Payables of $347000.0 for Q4 2025, up 149.64% on a YoY basis from $139000.0 in Q4 2024, and up 139.31% sequentially from $145000.0 in Q3 2025.
Guided Therapeutics (GTHP) Notes Payables (2011 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 15 years of Notes Payables data on file, last reported at $347000.0 in Q4 2025.
- For the quarter ending Q4 2025, Notes Payables rose 149.64% year-over-year to $347000.0; the trailing twelve-month figure through Dec 2025 stood at $347000.0 (up 149.64% YoY), and the FY2025 full-year result was $347000.0, up 149.64% from the prior year.
- Notes Payables rose to $347000.0 in Q4 2025, from $145000.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $579000.0 in Q3 2022 to a low of $23000.0 in Q1 2023.
- A 5-year average of $131882.4 and a median of $94000.0 in 2023 frame the typical range for Notes Payables.
- Across the five-year window, Notes Payables jumped 6400.0% in 2021 and sank 83.77% in 2023, its largest moves.
- Tracing GTHP's Notes Payables over 5 years: stood at $161000.0 in 2021, then slumped by 64.6% to $57000.0 in 2022, then surged by 64.91% to $94000.0 in 2023, then jumped by 47.87% to $139000.0 in 2024, then jumped by 149.64% to $347000.0 in 2025.
- Business Quant data shows GTHP's Notes Payables at $347000.0 in Q4 2025, $145000.0 in Q3 2025, and $24000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 347,000.00 |
| Sep 30, 2025 | 145,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 48,000.00 |
| Dec 31, 2024 | 139,000.00 |
| Sep 30, 2024 | 228,000.00 |
| Jun 30, 2024 | 112,000.00 |
| Mar 31, 2024 | 24,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Mar 31, 2023 | 23,000.00 |
| Dec 31, 2022 | 57,000.00 |
| Sep 30, 2022 | 579,000.00 |
| Jun 30, 2022 | 28,000.00 |
| Mar 31, 2022 | 31,000.00 |
| Dec 31, 2021 | 161,000.00 |
| Jun 30, 2021 | 65,000.00 |
| Mar 31, 2021 | 137,000.00 |
| Sep 30, 2020 | 116,000.00 |
| Jun 30, 2020 | 1,000.00 |
| Mar 31, 2020 | 740,000.00 |